Pateclizumab

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
Pateclizumab
Monoclonal antibody
Type Whole antibody
Source Humanized (from mouse)
Target lymphotoxin alpha
Clinical data
Synonyms MLTA3698A
ATC code
  • none
Identifiers
CAS Number
ChemSpider
  • none
KEGG
Chemical and physical data
Formula C6436H9910N1710O2004S44
Molar mass 144.7 kDa
 ☒N☑Y (what is this?)  (verify)

Pateclizumab (MLTA3698A) is an immunomodulator. It binds to lymphotoxin alpha.[1][2]

This drug was developed by Genentech/Roche.

References[edit]

  1. ^ World Health Organization (2011). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 105" (PDF). WHO Drug Information. 25 (2).[permanent dead link]
  2. ^ Statement On A Nonproprietary Name Adopted By The USAN Council - Pateclizumab, American Medical Association.